No large clinical end-point trials have been conducted comparing regimens among human immunodeficiency virus type 1-positive persons starting antiretroviral therapy. We examined clinical progression according to initial regimen in the Antiretroviral Therapy Cohort Collaboration, which is based on 12 European and North American cohort studies.
NOTE. 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; CDC, Centers for Disease Control and Prevention; D4T, stavudine; DDI, didanosine; EFV, efavirenz; IDU, injection drug use; IDV, idinavir; IQR, interquartile range; NFV, nelfinavir; NVP, nevirapine; PI, protease inhibitor; RTV, ritonavir; SQV, saquinavir.
only means of identifying potential differences in rates of clinical progression. Several studies have been undertaken [9] [10] [11] [12] [13] , but none to date has been large enough to examine differences in rates of clinical progression or death. The objective of the present study was to examine whether rates of progression differed according to initial HAART regimen among patients initiating therapy with either a NNRTI-or PI-based regimen.
METHODS

ART Cohort Collaboration (ART-CC).
The ART-CC is a multinational prospective study of ART-naive HIV-positive patients initiating HAART. The study has been described in detail elsewhere [14] [15] [16] [17] . It includes 12 cohort studies from Canada, Europe, and the United States: the French Hospital Database on HIV; the Italian Cohort of Antiretroviral-Naive Patients; the Swiss HIV Cohort Study; the AIDS Therapy Evaluation Project Netherlands; the Multicenter Study Group on EuroSIDA; Collaborations in HIV Outcomes Research-US; the Frankfurt HIV Cohort Study; the Aquitaine Cohort Study; the HAART Observational Medical Evaluation and Research Cohort Study, British Columbia Centre for Excellence in HIV/AIDS; the Royal Free Hospital Cohort Study; the South Alberta Clinic Cohort Study; and the Köln/Bonn Cohort Study. All cohort studies have been approved by institutional review boards, use standardized methods of data collection, and schedule follow-up visits at least once every 6 months. Patient selection and data extraction for the present study were performed at the cohorts' data centers. Anonymized data on a predefined set of demographic, laboratory, and clinical variables were pooled and analyzed centrally.
Statistical analyses. Analyses were restricted to patients who were HIV-1 positive, were у16 years old, had an HIV-1 RNA level у1000 copies/mL at treatment initiation, and first started HAART after 1 January 1996. The primary end points were death from any cause and the combined end point of a new AIDS-defining illness or death (AIDS/death). All centers used the 1993 US Centers for Disease Control and Prevention (CDC) criteria for the definitive or presumptive diagnosis of AIDS-defining opportunistic events [18] . A new AIDS diagnosis was defined as the first occurrence of each AIDS-defining condition; recurrences were not considered. Detectable HIV-1 RNA level (1500 copies/mL) and change in regimen at 6 months after initiation of HAART were secondary outcomes.
We measured time from the date of initiation of therapy to the date the end points occurred. For patients free of events, follow-up was censored either on the date of the most recent follow-up visit (for the combined end point) or on the date the patient was last known to be alive (for mortality). Cox regression was used to model the effect that initial treatment regimen and other prognostic factors have on disease progression [19] . All models were stratified by cohort (12 strata) and by calendar year of starting HAART (from 1996 onward, with 2002 and 2003 grouped together; 7 strata). We estimated hazard ratios (HRs) with 95% confidence intervals (CIs), comparing 8 third drugs: EFV, abacavir (ABC), a boosted PI (amprenavir, lopinavir, saquinavir [SQV], or IDV), IDV, NFV, NVP, ritonavir , and у100,000 copies/mL). Variables with Wald P 1 .2 were omitted from the final models. Analyses followed an "intent to continue initial regimen" principle, in that eligible patients were analyzed according to initial regimen, regardless of whether they later discontinued or modified their therapeutic regimen.
We compared the effect that initial regimen had on HIV-1 RNA levels and regimen change at 6 months. Logistic regression models were used to estimate the crude and adjusted odds ratios (ORs) for detectable HIV-1 RNA level (i.e., 1500 copies/mL), first for patients with available measurements at 6 months and second for all patients, using the combined-failure end point: detectable HIV-1 RNA level, death, or missing data on HIV-1 RNA level. Logistic models were also used to estimate the crude and adjusted ORs at 6 months for not receiving the initial regimen, first restricted to patients who had clinical follow-up measurements at 6 months (i.e., failure was considered to be either a change of drug regimen or cessation of HAART) and second for all patients (i.e., failure included regimen change, cessation of HAART, death, or missing data). Finally, we assessed whether there was evidence of between-cohort heterogeneity in the effects that initial regimen had on progression to AIDS/death by estimating the effect of initial regimen separately in each cohort and then combining these estimates by use of randomeffects meta-analysis. The proportion of the total variance due to heterogeneity between cohorts was estimated using the I 2 statistic [20] .
RESULTS
A total of 17,666 patients (55,622 person-years at risk) were available for analyses. A total of 1617 new AIDS events, 895 deaths, and 2017 AIDS cases or deaths were observed over the study period. Table 1 shows prognostic factors by initial drug regimen. The most common third drugs in a combination were IDV (26%), NFV (22%), and EFV and NVP (13%, for both). The most widely used NRTI pair was AZT/3TC (62%), followed by D4T/3TC (20%) and D4T/DDI (10%). The percentage of patients with AIDS ranged from 12% to 34%, and the percentage of patients with a history of IDU ranged from 9% to 26%. At initiation of treatment, the median CD4 cell count was lower in patients receiving RTV-boosted PIs than in patients receiving other regimens (130 vs. 240 cells/mL). The number and percentage of patients receiving each drug by cohort and by calendar year is shown in tables 2 and 3. Table 4 shows crude and adjusted HRs for AIDS/death and for death, for both third drugs and for NRTI pairs. When AIDS/ death was considered, the adjusted HRs were 1.28 (95% CI, 1.03-1.60) for NVP, 1.31 (95% CI, 1.01-1.71) for RTV, and 1.45 (95% CI, 1.15-1.81) for boosted regimens. There was little difference in the effect of the NRTI pairs. When mortality was considered, patients receiving EFV appeared to do best, but there was little evidence that the HR for death differed according to other third drugs, except for NVP: the adjusted HR relative to EFV was 1.65 (95% CI, 1.16-2.36). Compared with patients receiving AZT/3TC, the adjusted HR for death for patients receiving D4T/3TC was 1.35 (95% CI, 1.14-1.59). Again, there was little evidence of differences in rates according to other NRTI pairs. We found little evidence of between-cohort heterogeneity in the effect that the drugs had on clinical outcomes, except for RTV-boosted PIs ( ) and D4T/3TC
). The heterogeneity of the effect that RTV-boosted 2 I p 56% PIs had among cohorts might have been due to different PIs being prescribed. Table 5 shows crude and adjusted ORs for detectable HIV-1 RNA level at 6 months after initiation of HAART for each third drug and NRTI pair. Patients who started with EFV-containing regimens were more likely than patients who started with any other third drug to suppress HIV-1 RNA level by the 6-month time point: adjusted ORs for the comparison with EFV ranged from 1.67 (95% CI, 1.35-2.07) for boosted PIs to 5.33 (95% CI, 4.25-6.69) for SQV. These patterns were also seen when patients with missing data or who had died were considered to have experienced virological failure, although ORs were generally attenuated. Patients receiving other NRTI pairs were at greater risk of having a detectable HIV-1 RNA level at 6 months, compared with patients receiving AZT/3TC. Table 6 shows the crude and adjusted ORs for regimen change at 6 months after initiation of HAART for each third drug and NRTI pair. The drug most likely to result in regimen change In sensitivity analyses, we examined whether the NRTI pair modifies the effect of NFV (compared with that of EFV) by including an interaction term in the model. There was no evidence of interaction between EFV or NFV and the NRTI pairs for AIDS/death ( ) or for death ( ). However, there P p .36 P p .78 was evidence of interaction for the outcome of detectable HIV-1 RNA level at 6 months ( ) and of regimen change at P p .02 6 months ( ). For suppression of HIV-1 RNA level, EFV P p .04 was more effective with AZT/3TC than with D4T/DDI, but there was no evidence of a difference in efficacy between the NRTI pairs when combined with NFV. In light of the results for regimen change, it appears that the combination of EFV with D4T/DDI was less likely to be maintained than was AZT/ 3TC, whereas NFV was most frequently maintained with D4T/ DDI as the NRTI pair.
We examined whether the adjusted HR for NVP (compared with EFV) for all-cause mortality remained elevated if we restricted follow-up to 6 months, when patients were most likely to be still receiving their initial regimen. Compared with EFV, the adjusted HR for all-cause mortality for NVP was 2.28 (95% CI, 1.20-4.36) during the first 6 months, which decreased to 1.31 (95% CI, 0.81-2.18) after 6 months. We examined the hypothesis that, because of selective differences in toxicities, patients who initiated therapy at a high CD4 cell count would be at a greater risk of death if they were receiving NVP-based HAART than would those receiving other regimens. We believed that this difference would be especially pronounced in women and those who were positive for hepatitis C virus (HCV). Table 7 shows HRs for death, comparing NVP with all other third drugs in models including interaction terms for sex, high CD4 cell count (у350 cells/mL), and IDU, first for all patients and second restricted to patients with known HCV status. The data are consistent with the hypothesis that the risk of death is increased in women with high CD4 cell counts, especially those who are HCV positive. However, the power to detect interaction effects was low. We evaluated patterns of survival after 6 months of therapy, accounting for the initial response to HAART. The adjusted model controlled for CDC clinical stage, CD4 cell count, and HIV-1 RNA level at 6 months as well as age, IDU status, and clinical stage at initiation of HAART. At 6 months, compared with EFV, elevated crude HRs for mortality were observed for RTV (1.73 [95% CI, 1.02-2.91]) and for RTV-boosted PI regimens (1.76 [95% CI, 1.02-3.01]). However, these HRs were attenuated in the multivariable analysis, to 1.09 (95% CI, 0.64-1.87) for RTV and to 1.00 (95% CI, 0.58-1.73) for boosted regimens, suggesting that the higher HRs resulted from poor immunological and virological response during the first 6 months. The corresponding crude HR for NVP was 1.57 (95% CI, 0.97-2.54), which was attenuated to 1.33 (95% CI, 0.81-2.18). Therefore, the excess deaths in those who started with NVP, compared with deaths in those who started with EFV, might not have been the result of poor initial response. Among those who subsequently died, the mean CD4 cell count mea- We examined whether the effects of drug regimens differed according to whether patients' presumed transmission was via IDU. Models including and excluding the interaction between each third drug and IDU status were compared using likelihood ratio tests. In analyses that used separate models for IDU and non-IDU, the HRs for the third drugs were generally attenuated for non-IDU and increased for IDU. There was evidence only of an interaction between the third drug and IDU for NVP ( ). Results from analyses restricted to patients with a P p .05 history of IDU, patients without a history of IDU, patients with a baseline CD4 cell count 1200 cells/mL, and patients who started HAART after 1 January 1998 and for all patients but with followup censored at 2 years after starting HAART are presented in table 8. Censoring at 2 years did not affect estimates substantially. The HR for NVP was increased to 1.43 (95% CI, 0.97-2.10) in patients with a CD4 cell count 1200 cells/mL at initiation of HAART. When the analysis was restricted to those starting HAART after 1 January 1998, the HR for RTV was increased to 1.41 (95% CI, 0.96-2.08).
DISCUSSION
Thanks to a collaborative effort involving 12 different studies, the prognosis of HIV infection in patients initiating HAART could be elucidated for several initial regimens. We found that the choice of drugs used in the initial regimen was associated with the probability of viral suppression and with the sustained use of this regimen 6 months after starting HAART. We observed few differences in the rates of mortality between regimens, and these rates were much lower than were those in the pre-HAART era [21] . EFV performed the best of the third drugs, but several other drugs had similar effectiveness. Compared with EFV, the highest mortality risk was for patients who initiated HAART by receiving NVP.
In the absence of large trials, the present observational study provides important information on potential differences between regimens. Because all patients involved were treatment naive, our results were not confounded by previous ART and are relevant to many patients starting HAART. Data were combined across continents and countries, and our results should, therefore, be generalizable. Confounding is an important issue, because prognostic factors differed between groups of patients starting different regimens. Additional, unmeasured confounding factors could have distorted our results. Cox models were stratified both by cohort and by calendar year, and the results should not, therefore, be biased by between-cohort differences in treatment choices or by secular changes in the risk of the end points. AIDS diagnoses were not centrally reviewed or verified, which may have introduced bias due to misclassification. However, all cohorts used the same CDC criteria for the prospective diagnosis of AIDS-defining events, and study clinics are based in specialized centers with extensive expertise in HIV medicine. Some patients may have participated in clinical trials comparing different initial regimens, but it is likely that the proportion of such patients was small, and enrollment in the cohorts was independent of participation in trials.
HRs changed after adjustments were made for prognostic factors in multivariable models. In all cases except for NVP-based regimens, effects were attenuated. For example, in the unadjusted analysis, PI regimens boosted with RTV were associated with a 2-fold higher rate of AIDS/death (HR, 2.07), but this effect was considerably smaller after adjustments were made for prognostic factors (HR, 1.45), because these combinations were more likely to be prescribed to patients with more-advanced disease. Prognostic factors will have been subject to measurement error, and, therefore, it is possible that, because of residual confounding, the adjusted HR continues to be an overestimate of the true risk associated with boosted PI regimens. The opposite was the case for NVP-based therapies: patients at lower risk of progression were more likely to have received these regimens, and adjustment for prognostic factors at baseline, therefore, increased the HR for progression to AIDS/death, from 1.04 to 1.28. It is, therefore, possible that, because of residual confounding, the adjusted HR underestimates the true increase in the risk of progression associated with NVP.
Differences in outcome between EFV and NVP might have been the result of confounding by indication if patients with a poorer propensity to adhere tended to be prescribed NVP in preference to EFV. To distinguish this possibility from differences in discontinuation rates due to differences in efficacy or toxicity would require data both on reasons for choice of drug regimen and on reasons for discontinuation, which are difficult to collect. It is also important to consider whether observed differences could have been the result of differences in socioeconomic status [22, 23] . However, except for the United States, our patient populations came from countries where all individuals (with the possible exception of migrants of sub-Saharan African origin, who are not always legal migrants) had similar low-cost access to HAART and laboratory monitoring.
Our analyses did not account for adherence to treatment, because this information was not available. Formally, adherence to treatment cannot confound the effect of initial regimen, because it occurs subsequent to the choice of regimen. Rather, failure to adhere to treatment is likely to modify the effect of treatment, because poor adherence has been shown in previous studies to be associated with poor CD4 cell count and HIV-1 RNA response as well as mortality [24] [25] [26] [27] . However, choice of initial regimen might be affected by physicians' perception of the extent to which the patient is likely to adhere to treatment [25, 28, 29] , because different HAART regimens have clear differences in pill burden [28, 30] . This is reflected, for example, in the fact that presumed mode of transmission is associated with initial regimen. Unmeasured patient characteristics that affect propensity to adhere and also predict choice of regimen could confound our results.
Although our analyses were conducted on the basis of intent to continue initial regimen, 27% of patients were no longer receiving their initial regimen at 6 months after initiation. Those patients initially receiving RTV (46%) or RTV-boosted PIs (40%) were particularly likely to change regimens. To estimate the effect of initial regimen accounting for regimen change would be difficult, since regimen-specific factors (such as toxicities) will themselves be associated with regimen change.
Large variations in therapeutic responses by initial regimen have been observed previously. A recent meta-analysis of clinical trials comparing HAART regimens among persons with extensive ART experience demonstrated that unboosted PI regimens were clearly superior to NNRTI regimens based on NVP or delavirdine [31] . In particular, CD4 cell count response and the suppression of viral replication was found to be less for NNRTI regimens than for PI regimens. In contrast, a systematic review of trials evaluating HAART regimens in treatment-naive HIV-infected adults demonstrated that boosted PI and NNRTI regimens provided superior virological suppression than did PI and triple nucleoside-containing regimens [32] . However, boosted PI regimens showed the greatest increase in CD4 cell counts, compared with the other 3 regimen types.
Our results do not confirm the main findings from the 2NN trial [2] , although a sensitivity analysis in the 2NN trial, which included only those participants who received at least 1 dose of drugs, did find a significant benefit of EFV [2, 33, 34] . In our analysis, EFV appears to be more efficacious than any other third drug in a HAART regimen. These differences could be attributed to the superiority of EFV or might reflect underlying unmeasured differences in the ways in which physicians prescribe and patients use EFV, compared with other third drugs [28, [35] [36] [37] . Other observational studies have also suggested that EFV may be more efficacious than NVP with regard to CD4 cell count gain and virological efficacy [38, 39] . Of note, in our study, differences in viral load response were not generally associated with differences in rates of mortality, and differences in rates of mortality between EFV and NVP were associated with deaths that occurred during the first 6 months. These deaths could have been the result of either drug-induced toxicities or other factors not related to toxicity or therapeutic response [40] . The 2NN trial lacked the power to demonstrate, or to exclude with certainty, smaller differences in rates of mortality.
The present study arose from the need to characterize differences in response and survival by initial HAART regimen. No previous observational study has examined this issue with such a large patient population or large number of regimen types. Some of the third drugs analyzed here are no longer being prescribed in most settings, and there is a need for future work to examine regimens that have been prescribed in more recent years, once sufficient numbers of patients and follow-up time have accrued. The long-term impact of initial regimen choice may not be evident after 3 years of follow-up. It is not possible to simultaneously compare recently prescribed drug regimens and long-term effects-our approach represents a compromise between these 2 competing requirements.
In conclusion, the choice of drugs used in the initial HAART regimen is associated with the probability of viral suppression and with the sustained use of this regimen 6 months after the start of HAART. However, poorer response and higher rate of regimen change do not necessarily indicate subsequent differences in mortality. We cannot rule out confounding, rather than differences in drug effectiveness, as an explanation for our findings. Large clinical trials that are powered to assess differences in clinical outcomes are required to produce a more-definitive answer, and we strongly urge funding bodies to support such large, long-term trials in the future. 
